Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia

Elvira Sondo, Federico Falchi, Emanuela Caci, Loretta Ferrera, Elisa Giacomini, Emanuela Pesce, Valeria Tomati, Sine Mandrup Bertozzi, Luca Goldoni, Andrea Armirotti, Roberto Ravazzolo, Andrea Cavalli, Nicoletta Pedemonte

Research output: Contribution to journalArticle

Abstract

In cystic fibrosis (CF), deletion of phenylalanine 508 (F508del) in the CFTR channel is associated with misfolding and premature degradation of the mutant protein. Among the known proteins associated with F508del-CFTR processing, the ubiquitin ligase RNF5/RMA1 is particularly interesting. We previously demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice, validating the relevance of RNF5 as a drug target for CF. Here, we used a computational approach, based on ligand docking and virtual screening, to discover inh-02, a drug-like small molecule that inhibits RNF5. In in vitro experiments, treatment with inh-02 modulated ATG4B and paxillin, both known RNF5 targets. In immortalized and primary bronchial epithelial cells derived from CF patients homozygous for the F508del mutation, long-term incubation with inh-02 caused significant F508del-CFTR rescue. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability.

Original languageEnglish
Pages (from-to)891-905.e8
JournalCell Chemical Biology
Volume25
Issue number7
DOIs
Publication statusPublished - Jul 19 2018

Fingerprint

Ligases
Ubiquitin
Cystic Fibrosis
Epithelium
Pharmacology
Pharmaceutical Preparations
Paxillin
Mutant Proteins
Phenylalanine
Screening
Genetic Suppression
Ligands
Degradation
Molecules
Processing
Epithelial Cells
Proteins
Phenotype
Experiments
Mutation

Cite this

Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. / Sondo, Elvira; Falchi, Federico; Caci, Emanuela; Ferrera, Loretta; Giacomini, Elisa; Pesce, Emanuela; Tomati, Valeria; Mandrup Bertozzi, Sine; Goldoni, Luca; Armirotti, Andrea; Ravazzolo, Roberto; Cavalli, Andrea; Pedemonte, Nicoletta.

In: Cell Chemical Biology, Vol. 25, No. 7, 19.07.2018, p. 891-905.e8.

Research output: Contribution to journalArticle

Sondo, Elvira ; Falchi, Federico ; Caci, Emanuela ; Ferrera, Loretta ; Giacomini, Elisa ; Pesce, Emanuela ; Tomati, Valeria ; Mandrup Bertozzi, Sine ; Goldoni, Luca ; Armirotti, Andrea ; Ravazzolo, Roberto ; Cavalli, Andrea ; Pedemonte, Nicoletta. / Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. In: Cell Chemical Biology. 2018 ; Vol. 25, No. 7. pp. 891-905.e8.
@article{07364e099e094f0a9b42da91d38dd75b,
title = "Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia",
abstract = "In cystic fibrosis (CF), deletion of phenylalanine 508 (F508del) in the CFTR channel is associated with misfolding and premature degradation of the mutant protein. Among the known proteins associated with F508del-CFTR processing, the ubiquitin ligase RNF5/RMA1 is particularly interesting. We previously demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice, validating the relevance of RNF5 as a drug target for CF. Here, we used a computational approach, based on ligand docking and virtual screening, to discover inh-02, a drug-like small molecule that inhibits RNF5. In in vitro experiments, treatment with inh-02 modulated ATG4B and paxillin, both known RNF5 targets. In immortalized and primary bronchial epithelial cells derived from CF patients homozygous for the F508del mutation, long-term incubation with inh-02 caused significant F508del-CFTR rescue. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability.",
author = "Elvira Sondo and Federico Falchi and Emanuela Caci and Loretta Ferrera and Elisa Giacomini and Emanuela Pesce and Valeria Tomati and {Mandrup Bertozzi}, Sine and Luca Goldoni and Andrea Armirotti and Roberto Ravazzolo and Andrea Cavalli and Nicoletta Pedemonte",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "7",
day = "19",
doi = "10.1016/j.chembiol.2018.04.010",
language = "English",
volume = "25",
pages = "891--905.e8",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia

AU - Sondo, Elvira

AU - Falchi, Federico

AU - Caci, Emanuela

AU - Ferrera, Loretta

AU - Giacomini, Elisa

AU - Pesce, Emanuela

AU - Tomati, Valeria

AU - Mandrup Bertozzi, Sine

AU - Goldoni, Luca

AU - Armirotti, Andrea

AU - Ravazzolo, Roberto

AU - Cavalli, Andrea

AU - Pedemonte, Nicoletta

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/7/19

Y1 - 2018/7/19

N2 - In cystic fibrosis (CF), deletion of phenylalanine 508 (F508del) in the CFTR channel is associated with misfolding and premature degradation of the mutant protein. Among the known proteins associated with F508del-CFTR processing, the ubiquitin ligase RNF5/RMA1 is particularly interesting. We previously demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice, validating the relevance of RNF5 as a drug target for CF. Here, we used a computational approach, based on ligand docking and virtual screening, to discover inh-02, a drug-like small molecule that inhibits RNF5. In in vitro experiments, treatment with inh-02 modulated ATG4B and paxillin, both known RNF5 targets. In immortalized and primary bronchial epithelial cells derived from CF patients homozygous for the F508del mutation, long-term incubation with inh-02 caused significant F508del-CFTR rescue. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability.

AB - In cystic fibrosis (CF), deletion of phenylalanine 508 (F508del) in the CFTR channel is associated with misfolding and premature degradation of the mutant protein. Among the known proteins associated with F508del-CFTR processing, the ubiquitin ligase RNF5/RMA1 is particularly interesting. We previously demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice, validating the relevance of RNF5 as a drug target for CF. Here, we used a computational approach, based on ligand docking and virtual screening, to discover inh-02, a drug-like small molecule that inhibits RNF5. In in vitro experiments, treatment with inh-02 modulated ATG4B and paxillin, both known RNF5 targets. In immortalized and primary bronchial epithelial cells derived from CF patients homozygous for the F508del mutation, long-term incubation with inh-02 caused significant F508del-CFTR rescue. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability.

U2 - 10.1016/j.chembiol.2018.04.010

DO - 10.1016/j.chembiol.2018.04.010

M3 - Article

C2 - 29754957

VL - 25

SP - 891-905.e8

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 7

ER -